Clinical Trial

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2018-01-31; most recent amendment 2026-03-12.
Status change: Enrolling by Invitation → Active, Not Recruiting 2019-12-09
Trial Details
NCT Number NCT03424018
Lead Sponsor BioMarin Pharmaceutical
Conditions Achondroplasia
Enrollment 119 participants
Start Date 2017-12-12
Primary Completion 2031-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-13